AID-deficient Bcl-xL transgenic mice develop delayed atypical plasma cell tumors with unusual Ig/Myc chromosomal rearrangements

Alexander L. Kovalchuk,1,4 Wendy duBois,1 Elizabeth Mushinski,1 Nicole E. McNeil,2 Carsten Hirt,1,3 Chen-Feng Qi,4 Zhaoyang Li,4 Siegfried Janz,1,5 Tasuku Honjo,6 Masamichi Muramatsu,7 Thomas Ried,2 Timothy Behrens,8 and Michael Potter1

Activation-induced cytidine deaminase (AID) is required for immunoglobulin (Ig) class switch recombination and somatic hypermutation, and has also been implicated in translocations between Ig switch regions and c-Myc in plasma cell tumors in mice. We asked if AID is required for accelerated tumor development in pristane-treated Bcl-xL transgenic BALB/c mice deficient in AID (pBx Aicda−/−). pBx Aicda−/− mice developed tumors with a lower frequency (24 vs. 62%) and a longer mean latency (108 vs. 36 d) than AID-sufficient mice. The tumors appeared in oil granuloma tissue and did not form ascites. By interphase fluorescence in situ hybridization, six out of nine pBx Aicda−/− primary tumors had T(12;15) and one had T(6;15) chromosomal translocations. Two tumors were transplantable and established as stable cell lines. Molecular and cytogenetic analyses showed that one had an unusual unbalanced T(12;15) translocation, with IgH Cμ and Pvt-1 oriented head to tail at the breakpoint, resulting in an elevated expression of c-Myc. In contrast, the second was T(12;15) negative, but had an elevated N-Myc expression caused by a paracentric inversion of chromosome 12. Thus, novel mechanisms juxtapose Ig and Myc-family genes in AID-deficient plasma cell tumors.

Pristane-induced plasma cell tumors and those that develop spontaneously in BALB/c IL-6 transgenic mice carry either T(12;15) translocations between IgH and c-Myc (1–3) or T(6;15), T(15;16) between Ig light chain and Pvt-1 (4). These translocations activate and deregulate the transcription of the protooncogene c-Myc (5), and they are found in >95% of the plasma cell tumors, strongly suggesting that deregulation of c-Myc is a critical, and possibly the initiating, event in their development. Most of the IgH breaks occur in the Sμ or Sκ regions, although other rare rearrangements or insertions have been previously described (6–10).

Activation-induced cytidine deaminase (AID), which is encoded by the gene Aicda, has been shown to be essential for physiological class switch recombination and somatic hypermutation (11–13). Both class switch recombination and somatic hypermutation are associated with the generation of DNA double-strand breaks (DSBs). Two basic models have evolved to explain how AID contributes to the generation of these breaks. The first invokes deamination of cytidine in single-stranded DNA, followed by recruitment of uracil DNA glycosylase or...
mismatch repair proteins, leading to the generation of DSB and error-prone repair (14–16). There are also several lines of evidence that favor a second “RNA-editing” hypothesis, which postulates that AID functions as an mRNA deaminase that edits a putative precursor RNA, converting it to an mRNA encoding an endonuclease that cleaves IgH switch regions (17, 18).

Consistent with its role in creating DNA breaks in IgH switch regions, AID has been implicated in the etiology of canonical IgH/c-Myc translocations (19, 20). However, the role of AID in plasma cell tumor development has not been determined. In this study, we ask whether plasma cell tumors can be induced in Aida−/− mice by the intraperitoneal injection of pristane.

Most previous studies of Aida−/− mice used animals raised under specific pathogen-free (SPF) conditions. It was shown earlier that the incidence of pristane-induced plasma cell tumors is strikingly reduced in SPF-raised mice, and that high yields of these tumors require a conventional environment (21). Preliminary experiments with conventionally raised pBALB/c-Aida−/− resulted in deaths of the mice from a wasting syndrome that is attributed to an abnormal composition of gut flora, excessive lymphoid neogenesis (22), and reactivation of latent viruses.

To minimize these complications, we used an accelerated model of tumor induction. Previous studies showed that the time course for pristane-induced plasma cell tumor development was markedly increased in mice carrying a Bcl-2 transgene (23). Furthermore, Cheung et al. showed that the 3′Ex-Bcl-xL transgene cooperates with enforced expression of c-Myc to accelerate plasma cell tumor formation (24). In this study, we confirmed that constitutive expression of Bcl-xL greatly accelerated pristane-induced plasmacytoma development using BALB/c mice carrying a SV40-Epu-Bcl-xL transgene.

We backcrossed the Bcl-xL transgene onto a BALB/c-Aida−/− background to determine if AID-deficient mice can be induced to develop plasma cell tumors. We report that absence of AID had an inhibitory effect on plasma cell tumor induction by pristane. It resulted in a substantial delay in the emergence of atypical plasma cell tumors that did not grow in ascite form, had altered transplantability, and carried non-canonical translocations between c-Myc and IgH.

RESULTS

Acceleration and augmentation of plasma cell tumor development in pristane-treated BALB/c-Bcl-xL (Bx) transgenic mice

Mice carrying the SV40-Epu-Bcl-xL transgene, like Bcl-2 transgenics (25), spontaneously developed a low incidence of plasma cell tumors (19%) with long latencies of >300 d (Fig. 1 A and Table I). Injection of pristane into BALB/c-Bcl-xL transgenic mice resulted in a marked acceleration and greatly increased incidence of plasma cell tumors arising in the oil granuloma (Fig. 1 A). These mice first developed ascites containing tumor cells between 30 and 40 d after injection, and by day 140 77% of the mice had developed plasma cell tumors that were readily transplantable (5/5 tumors grew within 30 d).

The BALB/c-Bcl-xL mice were also crossed to C57BL/6 and DBA/2. These strains, as well as their F1 hybrids with BALB/c, are resistant to plasma cell tumor induction by pristane (26) (Fig. 1 A). In contrast, the incidence of plasma cell tumors in mice haploid for the Bcl-xL transgene was greatly increased, even though the latency was prolonged relative to that of pBxBALB/c mice. Thus, the Bcl-xL transgene was...
able to augment and accelerate plasma cell tumor development in these genetically resistant strains.

Effects of pristane injection on survival of conventional BALB/c Aicda−/− (pAicda+/−) mice

Groups of conventionalized Aicda−/− mice were raised on a diet with or without metronidazole to control the growth of anaerobic bacteria in the gastrointestinal tract (22) (Table S1 and Fig. S1, available at http://www.jem.org/cgi/content/full/jem.20070882/DC1). At various intervals after the intraperitoneal injection of pristane, pAicda−/− mice began losing weight, developing a hunched posture and ruffled fur. When weight loss or other signs became apparent, the mice were killed and autopsied. Others showed signs of a central nervous system (CNS) disorder, such as hind limb paralysis or ataxia. The cause of the CNS signs was not determined, but could be caused by activation of latent mouse hepatitis virus, which these mice are known to carry (unpublished data). The mean survival time for pAicda−/− mice was 130 d without and 155 d with metronidazole. The incidence of plasma cell tumors in these mice is known to carry (unpublished data). The mean survival time for pBxAicda−/− mice, but in smaller amounts than in pBxAicda+ mice, and they did not appear to contain suspicious tumorlike areas. Nonetheless, the oil granulomas were harvested and transplanted into pristane-conditioned BALB/c mice or fixed for histological studies. Unexpectedly, histologic studies revealed that some of these mice had plasma cell tumors in the mesenteric oil granulomas. 8/33 (24.2%) of pAicda−/− mice were found to have evidence of plasma cell tumor formation in oil granuloma tissue after 72–149 d (mean latency of 108 d; Fig. 1 B and Table II). An additional pBxAicda−/− plasma cell tumor, 4987, was discovered in a separate study, but was not included in the incidence figures for this experiment.

Plasma cell tumors induced by pristane characteristically spread from one site to another within oil granulomas. 3 of the neoplasms found in pBxAicda−/− mice involved >15 sites (advanced plasma cell tumors), 4 had 10 or more foci of atypical plasma cells (intermediate), and 2 had only 3–6 foci. The foci were located near or on peritoneal surfaces and involved multiple mesenteric polyplike structures, suggesting possible transperitoneal seeding (27).

The pBxAicda−/− plasma cell tumors exhibited a spectrum of morphological types from lymphocytoid plasma cells (5000) to well-differentiated plasma cells (4451) resembling Russell body cells (Fig. 2). There was also one example of a plasma cell tumor (4885) with morphological features typical of plasma cell tumors of Aicda+ or WT mice. Finally, consistent with deficiency of switched Ig classes in sera of humans and mice deficient in AID (13), all of these plasma cell tumors were shown by immunohistochemistry to express IgM and IgG, but no IgA or IgG as is typical of plasma cell tumors from AID-competent mice (unpublished data).

pBxAicda+ mice developed plasma cell tumors that were diagnosed by the appearance of tumor cells in the ascites between 50 and 130 d after pristane injection (mean latency of 86 d).

Table I. Summary of induction studies

| Figure | Pristane | Background genotype | Bcl-xL transgene | Aicda genotype | PCT/total | Mean latent period | Method of diagnosis |
|--------|----------|---------------------|------------------|---------------|-----------|--------------------|-------------------|
| 1 A    | −        | BALB/c              | +                | +             | 4/21 (19%) | 382                | Cytofuge          |
| 1 A    | +        | BALB/c N5           | +                | +             | 24/31 (77%) | 66                 | Cytofuge          |
| 1 A    | +        | BALB/c N5, LM       | −                | +             | 14/33 (38%) | 193                | Cytofuge          |
| 1 A    | +        | (BALB/c N5 x C57BL)F1 | +          | +             | 32/44 (72%) | 139                | Cytofuge          |
| 1 A    | +        | (BALB/c N5 x C57BL)F1 | −                | +             | 3/28 (10%)  | 269                | Cytofuge          |
| 1 A    | +        | (BALB/c N5 x DBA/2)F1 | +                | +             | 15/19 (79%) | 187                | Cytofuge          |
| 1 A    | +        | (BALB/c N5 x DBA/2)F1 | −                | +             | 0/19 (0%)   | −                  | Cytofuge          |
| 1 B    | +        | BALB/c              | +                | +             | 23/27 (62%) | 36                 | Histology         |
| 1 B    | +        | BALB/c              | −                | −             | 1/45 (2%)   | 132                | Histology         |
| 1 B    | +        | BALB/c N7           | +                | +             | 8/33 (24%)  | 108                | Histology         |

B/c, BALB/c; LM, littermates; N, backcross generation; PCT, plasma cell tumor.
cell tumors also differed from tumors of AID-competent mice in their ability to grow in secondary recipients.

**Exaggerated lymphoid neogenesis in tissues of pBxAicda−/− mice**

When compared with the pAicda−/− mice, the pBxAicda−/− mice had additional complications that were caused by excessive lymphoid hyperplasia in the form of lymphoid aggregates, which were previously described as lymphoid neogenesis (28, 29). Numerous lymphoid aggregates were found in the wall of the small intestine and the lamina propria of the intestinal villi, with some presenting as isolated lymphoid follicles (22, 30).

Both transplantable tumors (4885 and 4961) were established in tissue culture as cell lines. They exhibited a mature plasma cell phenotype (CD45−, CD138+, PC-1+, CD19−, and CD23−), secreted IgM, and were clearly of donor origin, as they were shown to carry the Bcl-xL transgene by PCR analysis and carried both Aicda−/− alleles. In contrast to all previously studied mouse plasma cell tumors, both cell lines were found to express CD5 cell surface marker, and 4961 had intermediate expression of CD11b by FACS analysis (unpublished data). We conclude that atypical plasma cell tumors develop in pBxAicda−/− mice and that they appear at a much slower rate than in AID-sufficient mice. pBxAicda−/− plasma cell tumors also differed from tumors of AID-competent mice in their ability to grow in secondary recipients.

### Table II. Characteristics of plasma cell tumors in pBxAicda−/− mice

| Mouse#  | Post pristane | Oil granuloma no. foci | Transplant to pristane-primed recipient | FISH |
|---------|---------------|------------------------|-----------------------------------------|------|
| 3935    | 77            | 20                     | no growth                               | +T(12;15) |
| 4885    | 72            | 20                     | +4 mo                                   | +T(12;15) |
| 4451    | 102           | 6                      | no growth                               | +T(12;15) |
| 4961    | 111           | 15                     | +4 mo                                   | Inv(12) |
| 4592    | 149           | 13                     | no growth                               | negative |
| 5000    | 84            | 3                      | no growth                               | +T(12;15) |
| 5008    | 133           | 13                     | no growth                               | +T(6;15) |
| 5047    | 135           | 6                      | no growth                               | +T(12;15) |
| 4987    | 127           | 11                     | no growth                               | +T(12;15) |

Because none of the pBxAicda−/− mice developed ascites, the diagnosis of plasma cell tumors in these mice had to be made retrospectively by microscopic analyses of tissue sections. To make direct comparisons with other groups, we examined tissue sections from 37 pBxAicda+ mice for atypical plasma cell focus development between days 14 and 49 after pristane (Fig. 1 B). Mice with one or more foci were considered positive. The plasma cells in these foci were hyperchromatic and resembled cells characteristic of plasma cell tumors. The mean latency after pristane for tumor development in the 21 positive mice was 36 d.

pBxAicda−/− plasma cell tumors proved to be difficult to transplant, whereas plasma cell tumors of pBx mice were readily transplantable and grew out within 30 d. We consider completely transformed plasma cells to be transplantable. There are several possible explanations for this. First, we were not able to establish the clonality of the primary tumors in pBxAicda−/− mice by immunohistochemistry, PCR, or Southern blotting. Second, in mice with few foci (4451, 5000, and 5047), it is possible that the transplanted tissue fragments did not contain a tumor focus (Table II). Third, the more advanced cases (4885 and 4961) that did grow in transplant differed from pBxAicda+ tumors by taking 4 mo to grow out in pristane-conditioned BALB/cAn mice. Furthermore, one of the two more advanced tumors (4961) did not grow out in efforts to passage it a second time. This could be evidence of incomplete transformation.

Figure 2. Photomicrographs of four plasma cell tumors arising in pBxAicda−/− mice that show variations in plasma cell morphology. 4885 resembles tumors found in WT mice. The most undifferentiated, 5000, resembles lymphocytoid plasma cells. They have the least amount of cytoplasm, which consists of a thin rim around the nucleus. 4451 contains many cells with Russell body-like features, as well as cells with mature plasma cell morphology. 4961 is an early plasma cell tumor showing many small plasma cells that differ in size from the common types of plasma cell tumors that are well known to contain near tetraploid numbers of chromosomes. Bar, 20 μm.
Cells were examined using 3D view (Fig. 3, C and D), and IgH/c-Myc gene colocalization was confirmed.

The proportion of cells with fusion signals in pBxAicda−/− plasma cell tumors (3935, 4451, 4987, 4885, 5000, and 5047) ranged from 34 to 63%. In pBxAicda+/− plasma cell tumors, the proportions ranged from 29 to 57% (Table S2, available at http://www.jem.org/cgi/content/full/jem.20070882/DC1). Samples from different parts of a tumor showed variations in the proportion of positive cells, which may be caused by varying contributions of stromal or other nontumor cells.

As controls, five samples of lymphoid hyperplasia or extramedullary myelopoiesis, taken from the same oil granuloma tissue sections, showed 0–2.6% of cells with a fusion signal. These data were used to establish a value of 4.1% (four standard deviations above the mean) as identifying translocation-bearing plasma cell tumors. Based on these calculations, three additional plasma cell tumors from pBxAicda−/− mice (4961, 5008, and 4592) were scored as T(12;15) negative.

Tissue sections of tumors negative for T(12;15) were hybridized with probes specific for IgK on chromosome 6 and for c-Myc to detect T(6;15), which is a translocation found at lower frequency than T(12;15) in plasma cell tumors of AID-sufficient mice. Tumor 5008 was positive for IgH/c-Myc co-localization, with 55% of cells positive for fusion signals, this is in comparison to a plasmacytic focus from the same section, with only 3.5% positive cells.

PCR and Southern blot hybridization studies of primary plasma cell tumors and cell lines

The frequency of T(12;15) in pristane-induce plasma cell tumors of WT mice is ~80% (31). The vast majority of either

Figure 3. Interphase FISH on tissue sections showing IgH/c-Myc colocalization in pBxAicda−/− plasma cell tumor 4885. (A and C) Two- and three-dimensional photomicrographs of interphase nuclei from a cell with no evidence of T(12;15) translocation: two red (IgH) and two green (c-Myc) signals. (B and D) A cell with a fused signal indicative of T(12;15), doublet Red (IgH) resulting from hybridization to two sister chromatids, and two green (c-Myc) signals. Grid, 1 μm. Bars, 1 μm.
der(12)T(12;15) or der(15)T(12;15) breakpoints can be amplified by PCR (32, 33). To determine the nature of the translocations in pBxAicda−/− plasma cell tumors, we performed PCR reactions using long PCR (covering VDJ-Eμ, Cμ, Cγ1, Cγ2b, Cγ2a, Cε, and Cα), as well as PCR with switch region degenerate primers. We were unable to amplify products containing c-Myc and IgH chimeric sequences (unpublished data). As controls, we analyzed seven pBxAicda−/− tumors, five of which were positive (Table S3, available at http://www.jem.org/cgi/content/full/jem.20070882/DC1). Thus, the

![Figure 4. Molecular and cytogenetic analysis identifies the T(12;15) chromosomal translocation in the pBxAicda−/− cell line, 4885.](image)

(A) A representative karyotype of cell line 4885 analyzed by SKY shows a subtle translocation involving chromosome 12 and 15 as indicated by the arrow. (B) FISH using whole chromosome painting probes confirms a T(12;15) (arrow). Metaphase chromosomes are DAPI-stained. The normal chromosome 12 is depicted in red, and the normal chromosome 15 is shown in green. (C) FISH with gene-specific probes confirmed the involvement of c-Myc and IgH in the chromosomal rearrangement. Within the DAPI-stained metaphase, probes for c-Myc (green) and IgH (red) are colocalized on the abnormal chromosome (arrow). Additionally, c-Myc signals are present on the normal chromosome 15, whereas the signal for the IgH gene appears on the normal chromosome 12. (D) aCGH profile of the 4885 cell line. Locations of IgH Cm (chromosome 12, top plot) and Pvt-1 (chromosome 15, bottom plot) are indicated by arrows pointing up. Translocation breakpoints (Tx) are depicted by arrows pointing down. Bars, 5 μm.
translocations in pBxAicda−/− mice take place in unusual locations and are unlikely to involve switch regions.

Southern blots performed with DNA isolated from cell lines 4885 and 4961 showed that the c-Myc gene was in germline configuration and not amplified (unpublished data). Analysis of Jκ rearrangements in these tumors revealed the absence of a germline band and the presence of two rearranged bands in the translocation-negative cell line (4961) and a single rearranged band in the T(12;15)-positive cell line (4885; Fig. S3, available at http://www.jem.org/cgi/content/full/jem.20070882/DC1). This indicates that in 4885, one copy of the J-C intron was completely lost as the result of a nonreciprocal T(12;15) translocation.

Consistent with the Southern blot data, 4885 carried and expressed a single rearranged heavy chain allele (Vh J558, 17-DSP2.13-Jh4). 4961 carried both alleles; one productively rearranged (J558.41-DSP2.7-Jh2) and another with stop codons (J558.41-DSP2.2-Jh2). DNA sequences of expressed VhDHJh genes had no mutations (unpublished data).

pBxAicda−/− plasma cell tumor cell lines exhibit atypical IgH/Myc rearrangements

The pBxAicda−/− cell line derived from tumor 4885 was analyzed by spectral karyotyping (SKY) and showed a near diploid karyotype of 39−42, XY, +1, +15, der(12)T(12;15) in at least 15 metaphase spreads (Fig. 4 A). The translocation was rather subtle because the telomeric portion of chromosome 15 appeared smaller then usual. FISH analysis using whole chromosome painting probes for mouse chromosome 12 and 15 confirmed the presence of a T(12;15) (Fig. 4 B). Further analyses with gene-specific probes identified a juxtaposition of IgH and c-Myc (Fig. 4 C), the absence of a reciprocal chromosome der(15)T(12;15) and the presence of an extra copy of "normal" chromosome 15. Therefore, a nonreciprocal T(12;15) may have originated in a cell with a trisomy of chromosome 15, which is a frequent occurrence in mouse B cell and T cell lymphomas, but is almost never seen in diploid mouse plasma cell tumors (34).

Because of the unbalanced T(12;15) in 4885, we used NimbleGen’s high-resolution array comparative genomic hybridization (aCGH) to map translocation breakpoints. Analysis of an array CGH profile of chromosome 12 shows gross deletions in the 5′Igh locus, which is typical for VDJ recombination events (Fig. 4 D, top plot). Additionally, it shows the loss of one copy of the telomeric portion of chromosome 12 (log2 ratio of −0.5) starting at ~650 bp upstream of the first exon of IgH Cμ, which approximates the approximate position of the translocation breakpoint (Fig. 4 D and Fig. S4, available at http://www.jem.org/cgi/content/full/jem.20070882/DC1). This deletion is also consistent with the loss of der(15)T(12;15).

In contrast, alterations of chromosome 15 appear to be much more complex and show six regions of gains, including one in the telomeric portion (log2 ratio of 0.25; Fig. 4 D, bottom plot). This finding suggests multiple deletions of der(12). We used FISH with bacterial artificial chromosomes (BACs) aligned to the regions of gains and reconfirmed their presence on all copies of chromosome 15 and der(12)T(12;15). BAC 6212 that corresponds to the distal portion of chromosome 15 in the region showing no gain, hybridized only to 2 “normal” copies of chromosome 15. The schematic structure of der(12) chromosome is presented in Fig. S4.

Because the location of the translocation breakpoint was scrambled for chromosome 15 and straightforward for chromosome 12, we resorted to inverse PCR using IgH Cμ primers to amplify the junction. Sequence analysis identified the breakpoint location on chromosome 12 just 211 bp upstream of the first exon of IgH Cμ, which is very close to the breakpoint predicted by aCGH (see above). The chromosome 15 breakpoint was ~75 kb downstream of c-Myc, which was joined with IgH in a head-to-tail orientation that is unusual for T(12;15) translocations. This finding suggests that chromosome 15 underwent a paracentric inversion involving the c-Myc locus before or during illegitimate recombination with chromosome 12 (Fig. S4). Consistent with the aCGH data, the Prt-1 locus was allocated to der(15) and cannot be detected with RP23-96F18 BAC on der(12) (Fig. S4). ABPC60 is the only known plasma cell tumor with a T(12;15) to have the breakpoint 3′ of c-Myc (9). Moreover, before this study, the closest known breakpoint to IgH Cμ (914 bp 5′) was in a BALB/c pristane-induced tumor PCT 4130 (unpublished data). We conclude that the breakpoint location in 4885 is atypical compared with other mouse plasma cell tumors with T(12;15).

For the pBxAicda−/− cell line 4961, 10 complete metaphases were analyzed by SKY and showed a near diploid karyotype of 40, X, T(1;10), +6, In(12), T(10;1) (Fig. 5 A). One copy of chromosome 12 showed an abnormal inverted DAPI pattern suggestive of a paracentric inversion (Fig. 5 B). We performed additional metaphase FISH studies to identify the genes affected by the inversion. Using FISH with 3′IgH-(green) and 5′IgH-specific (red) probes, we uncovered the relocation of IgH 3′ locus control region from its usual telomeric site toward the centromere (Fig. 5 C) and colocalization of the 3′IgH probe (green) with a BAC probe for N-Myc (red) on inv(12) (Fig. 6 D). Ideograms of the normal and the inverted chromosome 12 are drawn in Fig. 5 D. An aCGH analysis of chromosome 12 did not reveal any sizable deletions associated with the inversion or amplifications (unpublished data). Consistent with the PCR and Southern blot analysis data described previously, we propose that the inversion must have occurred upstream of the rearranged VDJ segment. It is not yet clear if the inversion involved the expressed or the nonexpressed allele. The break site in the vicinity of N-Myc must have occurred within 200 kb telomeric to the gene. A proposed structure of this novel chromosome 12 inversion in 4961 is presented in Fig. S4.

Up-regulated expression of c-Myc or N-Myc in pBxAicda−/− cell lines

To establish that the observed genomic rearrangements, indeed, resulted in activation of adjacent oncogenes, we compared
expression of c-Myc and N-Myc mRNA in pBxAicda<sup>−/−</sup> and pBxAicda<sup>+/+</sup> cell lines using quantitative PCR (qPCR). Expression of c-Myc was comparably elevated in all cell lines except for 4961 that expressed a high level of N-Myc message (Fig. 6).

**DISCUSSION**

In this study, we showed that plasma cell tumors can be induced in pristane-treated BALB/c-Bcl-xL Aicda<sup>−/−</sup> mice. These tumors, however, are characterized by a reduced frequency and prolonged latency when compared with plasma cells tumors of pristane-treated AID-competent mice. The plasma cell tumors in the pBxAicda<sup>−/−</sup> mice also differed from those arising in pBxAicda<sup>+</sup>, as six were apparently in early or intermediate stages of progression and most could be diagnosed only retrospectively by studies of histologic sections.

The pBx-Aicda<sup>−/−</sup> mice did not develop ascites, a process that facilitates diagnosing plasma cell tumors by paracentesis. Thus, one of the important signs of tumor development was not present. Finally, most of these tumors had not progressed to become fully autonomous malignancies. In summary, AID is essential for the usual development and progression of pristane-induced plasmacytomas. Nevertheless, atypical plasma cell tumors can arise in the absence of AID.

Using interphase FISH in paraffin sections, we found evidence of T(12;15) chromosomal translocations in 6 of the 9 pBxAicda<sup>−/−</sup> tumors studied (Table II). In these samples, 35–63% of the cells in the tumor-containing regions exhibited fusion signals that were interpreted as indicative of T(12;15) translocations. Our initial expectation was that in the absence of AID the I<sub>κ</sub>K/Pmt-1 recombination would be preferred. However, we found a T(6;15) in only one tumor, 5008.
velop in mice deficient for both coamplified with early stages of B cell development, and was found to be the majority of (36). However, in mouse plasma cell tumor development was previously shown (49, 61) that pBx Aicda−/− cell lines 4961 and 4885 to pBx Aicda+/+ controls.

JEM VOL. 204, November 26, 2007

Figure 6. Comparison of c-Myc and N-Myc transcript levels in pBx Aicda−/− cell lines 4961 and 4885 to pBx Aicda+/+ controls.

(A) Summary of qPCR analysis of c-Myc and N-Myc. Numbers indicate the log2 transformed fold change. Data are mean expression from three independent experiments. (B) Agarose gel electrophoresis of qPCR products. 10 μl of qPCR reaction were loaded on 2% agarose gel and visualized by ethidium bromide staining.

A surprising finding was the activation of N-Myc by a para-centric inversion of chromosome 12 in tumor 4885. The sole previous example of N-Myc activation and deregulation in mouse plasma cell tumors resulted from the juxtaposition of Igκ and N-Myc loci in an exceptional mouse plasma cell tumor, ABPC-132, which carries a reciprocal T(6;12) translocation (35). Functional homology between N-Myc and c-Myc in mouse plasma cell tumor development was previously shown (36). However, N-Myc is normally expressed only during the early stages of B cell development, and was found to be coamplified with IgH in B cell progenitor tumors that develop in mice deficient for both p53 and Artemis (37). Thus, the majority of Aicda−/− plasma cell tumors similar to those developing in their AID-sufficient counterparts are predisposed to T(12;15) translocations.

Unniraman et al., using highly sensitive PCR methodologies, recently studied lymphoid tissues in pristane-treated BALB/c Aicda−/− mice to determine if they contained evidence of switch-related T(12;15) (38). Sequences of the junctional fragments obtained from the tissues harvested at 2–4 wk after pristane showed that breakpoints occurred in IgH switch regions. They did not find similar PCR fragments 3–5 mo later. It was not determined if these tissues contained plasma cell tumor cells. The explanation for these findings awaits further clarification. Although we did not study the early response to pristane, we were not able to detect IgH/c-Myc illegitimate recombinations in five samples containing pBx Aicda−/− plasma cell tumors by using PCR primers used in the Unniraman study or any other primer combination with the exception of C8 and Cy3 (Table S4, available at http://www.jem.org/cgi/content/full/jem.20070882/DC1). Our results are in agreement with those of Ramiro et al. (19), who, using another plasma cell tumor induction system, did not detect canonical IgH/c-Myc translocations in IL6-transgenic Aicda−/− mice.

Molecular and cytogenetic analyses of illegitimate recombinations in 4885 and 4961 pBx Aicda−/− cell lines showed no involvement of switch regions or sequences in close proximity to c-Myc. This differs from most T(12;15)-positive plasma cell tumors in AID-competent mice (5). A mechanism for generating “untargeted” single-strand DNA breaks and DSB, one that does not depend on special features of switch regions and also involves c-Myc, is a potential explanation for our findings. This possibility is supported by earlier studies showing that occasional pristane-induced plasma cell tumors in BALB/c mice have unusual rearrangements of c-Myc and Ig genes (6–10). Although our experiments confirm the importance of AID in mediating canonical IgH/c-Myc translocations, they also establish the existence of additional mechanisms that can lead to illegitimate recombination of Ig genes with an oncogene in the absence of AID.

Several studies have described B cells and B cell lymphomas with “unusual” illegitimate recombinations of chromosomes 12 and 15. These studies have used mice with two types of genetically engineered abnormalities. The first involved mice deficient in proapoptotic signaling as a result of homozygosity for a p53 knockout or by constitutive expression of an antiapoptotic gene, either Bcl-2 or Bcl-XL. The second category is associated with defects in genes involved in DNA damage control (sid, ATM, H2AX, 53BP-1, and Nbs-1) or in nonhomologous end joining (XRCC4, Ligase IV, Ku70/80, DNA PKcs, and Artemis) (39–46). Tumors associated with these defects predominantly occurred in pro-B cells and contained IgH/c-Myc chromosomal translocations. Amplifications, termed complicons, that generated additional illegitimate IgH/c-Myc recombinations, sometimes three-way, have also been described in these tumors (41, 47–49). It was proposed that the DSBs leading to these illegitimate recombinations were associated with RAG1/2 activity, as they occurred between Vκ and Cμ (41, 47, 48). The mechanism of DNA end joining in these tumors may involve the recognition of microhomologies (50, 51).

Alternative pathways of generating DSBs may target the genomes of B cells, and could be responsible for the aberrant generation of T(12;15) seen in pBx Aicda−/− mice. It has been shown that microenvironments that produce oxidants may cause DSBs or lead to neoplastic transformation (52, 53). The pristane-induced oil granuloma in BALB/c mice contains an abundance of neutrophils, particularly in the early stages of its formation, which generate oxidants and other products that have been shown to damage DNA (54). Shacter et al. cocultured plasma cell tumor cells with purified neutrophils in vitro
and found DNA damage in the target cells (55). Some oxidants may arise from endogenous metabolism (56, 57). Also the “endogenous DSB” process occurs during normal DNA replication generating an estimated 50 DSB/nucleus in a cell cycle (58). We are currently unaware of the tissue site in which these DSBs take place. It could be in an extrapertitoneal site, such as bone marrow, spleen, or gut-associated lymphoid tissue, or in the oil granuloma itself.

The roles played by enforced expression of Bcl-xL or Bcl-2 in the B lineage and the mechanisms by which they contribute to accelerating plasma cell tumor development are not established. The Bcl-xL transgene, as shown by Fang et al. (59), acts during early B cell development in the bone marrow to give a 4–5 fold expansion of the pro-B cell compartment and permits the survival of pro-B cells that have undergone nonproductive V-D-J rearrangements and extensive D1 or J5 deletions (59, 60). Transgenic Bcl-xL may also exert significant effects in peripheral B cells and plasma cells.

In this study, enforced expression of Bcl-xL under the control of the Eq enhancer and SV40 promoter activates and expresses an antiapoptotic protein, and it acts as a functional equivalent to homozygosity for a null mutation of p53. Although the pathway of action of p53, a transcriptional transactivator, and Bcl-xL, an inhibitor of mitochondrial apoptosis (61), may differ, they potentially accomplish a common end result, which is a failure to eliminate cells that have experienced illegitimate recombinations, which may mark the initiation of neoplastic progression. It should be noted, however, that p53 has many other functions such as governing cell cycle checkpoints and DNA replication (62). In addition, p53 deficiency may promote DNA amplifications (63, 64). Ranuro et al. have postulated that there may be a surveillance mechanism mediated by p53 for detecting and eliminating cells that carry translocations (20). The constitutive expression of the antiapoptotic factor Bcl-xL may promote the survival of cells with T(12;15) that express relatively large amounts of Myc that otherwise would drive the cells into apoptosis (65, 66). B cells that harbor these translocations are able to progress slowly into atypical plasma cell dyscrasias reminiscent of indolent states of B cell neoplasia in humans. We conclude that rapid development of malignant plasma cell tumors with reciprocal T(12;15) does require AID, and that in AID deficiency other, less efficient mechanisms can be used to bring c-Myc and Ig genes into juxtaposition. The reason why recombinations between IgH and c-Myc occur so regularly in mouse plasma cell tumor formation is thought provoking and, as yet, an unexplained problem.

MATERIALS AND METHODS

Mice. All animals were maintained under NCI IACUC-approved protocols LG023, LG024, and LG025. The mice were fed Purina Mouse Chow 5001 ad libitum and sterilized acidified drinking water. The SV40-Eq-Bcl-2 transgene was originally developed by Strasser et al. (25) and modified by Grillot et al. (67) by replacing human Bcl-2 with human Bcl-xL. The SV40-Eq-Bcl-xL transgene, which was originally developed on hybrid backgrounds, was reintrogessively backcrossed onto conventionally raised BALB/cAnPt mice for six generations in the Laboratory of Genetics (NCI) to generate BALB/c-Bcl-xL transgenic mice. The allele mice developed by Muramatsu et al. (12) were backcrossed four or more generations onto BALB/cKyoto in Kyoto University and transferred to the NCI in 2003 as SPF mice. In 2004, they were introduced into the NCI conventional facility, where they were maintained in filter-top cages and fed sterile water and a balanced-flavored diet that contained 138 mg/kg metronidazole (Bioserve) to control the microbial flora. BALB/cAnPt-Bcl-xL transgenic mice were crossed to BALB/c(Kyoto)-Aicda+/− mice at backcross N4, and the F1 hybrids were crossed to each other to produce F2. The following six genotypes were obtained: Bcl-xL+/−; Aicda+/+, +/−, and −/−; WT; Aicda+/+, +/−, and −/−. Mice of all six genotypes were inoculated intraperitoneally with 0.4 or 0.5 ml pristane (Aldrich Chemical) at 2 mo of age, and a second injection of pristane was given 60 d later.

Sample preparation. Tissues were fixed in Fekete’s modified Telyeuxizc’s fluid (70% ethanol/formalin/glacial acetic acid in 20:2:1 parts) for 24–48 h and transferred to 70% ethanol in buffered saline. These specimens were embedded in paraffin and sectioned at 4–5 μm by HistoServ. To prepare metaphase chromosomes ~10 cultured cells were first lysed and then fixed in 3:1 methanol/acidic acid solution. An aliquot of the suspension was dropped onto a glass slide in a controlled temperature (20–25°C) and humidity (45–55%) environment of a Thermotron. Total RNA and genomic DNA were isolated according to the manufacturer’s instructions using TR1 reagent (Sigma–Aldrich) and Pungence system (Gentra Systems) correspondingly. cDNA was obtained using a kit from Roche.

Plasma cell tumor diagnosis. Plasma cell tumors in pristane-treated BALB/c mice were diagnosed using Wright-Giemsa--stained cytotoxic preparations of ascites. The presence of 10 tumor cells per field was scored as a positive. Most positive mice lived for several weeks, and the number of tumor cells increased to >100 per cytotoxic field. Because pBxAicda+/− mice did not develop ascites, we used hemotoxylin and eosin--stained sections of oil granulomas to determine the number of foci with 50 or more atypical plasma cells.

Transplantation and in vitro culture. Tumor transplants were initiated by the injection of finely minced oil granuloma tissue into syngeneic BALB/cAnPt mice that had been injected intraperitoneally with 0.2–0.5 ml pristane 1–15 d before transplantation. Cell lines were established from generation 1 transplants by culturing in complete RPMI 1640 medium supplemented with 10% fetal calf serum and 10 ng/ml IL-6. To ensure that the cell lines were not derived from plasma cell tumors of host origin, the tumor tissues were shown by PCR to carry the human Bcl-xL transgene (68) and both targeted alleles of Aicda (12).

Immunohistochemistry, ELISA, and FACS. PNA (Vector Laboratories), anti-B220 (BD Bioscience), -IgM, -IgG, -IgA, and -IgK (Southern-Biotech) were all conjugated to biotin and reacted directly with sectioned tissue, followed by avidin conjugated to either alkaline phosphatase or peroxidase. Standard ELISA isotyping techniques were applied using mouse serum or concentrated tissue culture supernatant as the antigen at an initial dilution of 1:500. We used goat anti-mouse IgA, IgG1, IgG2a, IgG2b, IgG3, and IgM HRP-conjugated antibodies (SouthernBiotech). Cell surface markers were analyzed using a FACS Calibur (Becton Dickinson) after the cells were stained with FITC-, PE-, APC-, or PerCP-conjugated antibodies specific for mouse CD45, CD19, CD138, PC-1, CD23, CD5, and CD11b (BD Biosciences).

Cyogenetic analysis of plasma cell tumors. SKY was performed as previously described (69). SKY image acquisition was performed using the SpectraCube SD200 (Applied Spectral Imaging) connected to an epifluorescence microscope (DMXKA; Leica). Image analysis was done using SKYVIEW program version 1.6.2 (Applied Spectral Imaging). FISH was performed on metaphase chromosomes and interphase nuclei according to standard protocols (http://www.ncdlab.nci.nih.gov/protocols.asp#h3) using whole-chromosome
painting probes, as well as gene-specific probes for IgH and c-Myc. The mouse whole-chromosome paints were labeled by degenerate oligonucleotide primer PCR. Mouse chromosome 12 was labeled with Biotin (Roche) and detected with streptavidin-Cy3 (GE Healthcare), whereas mouse chromosome 15 was directly labeled with Spectrum Green (Vysis). The images were acquired using a DMRXA epifluorescence microscope equipped with a SenSys charge-coupled device camera (Roper Scientific).

BAC clones containing c-Myc located on mouse chromosome 15D2-3 (D15Mit17), Pot 1 gene adjacent to c-Myc (RP23-96F18), the Cy3-Ca constant regions of 3' IgH on chromosome 12F1 (189A22), 5' IgH variable region on chromosome 12F2 representing the distal end of the Vh cluster (VJ88; Vh2-224M14, provided by M. Takizawa, National Institute of Arthritis, Musculoskeletal and Skin Diseases [NIAMS], Bethesda, MD), Igk on chromosome 6C2 (RP23-451H4), N-Myc on chromosome 12A2 (RP23-246B9; provided by C. Yan, Harvard Medical School, Boston, MA), and 240 kb telomeric to N-Myc (RP23-225P23) were labeled using digoxigenin or biotin-nick translation kits (Roche). Detection was performed using streptavidin Alexa Fluor 568 (Invitrogen) and sheep anti-digoxigenin-fluorescein or Cy3 (Amersham). Mouse chromosome 12 was labeled with Biotin (Roche) and detected using streptavidin-Cy3 (GE Healthcare), whereas mouse chromosome 15 was directly labeled with Spectrum Green (Vysis). The images were acquired using a DMRXA epifluorescence microscope equipped with a SenSys charge-coupled device camera (Roper Scientific).

Confocal z stack images of tissue sections taken at 0.5-μm intervals were acquired on a fluorescent microscope (IX81; Olympus Optical) with a 100× oil lens using Slidebook software v.4.1.0.16 (Intelligent Imaging Innovations). All images were deconvolved, and merged pseudocolor maximum projections were generated. Using the ImageJ program (http://rsb.info.nih.gov/ij), the DAPI-stained nuclei in the photographic field were outlined and numbered. Each nucleus was evaluated for the presence of red (IgH), green (c-Myc), and yellow (fused) signals. Nuclei were counted in 1–3 photographic fields, and the proportion of nuclei with fusion signals was determined.

aCGH. High-resolution CGH analysis was performed by NimbleGen Systems using part of a whole-mouse genome tiling set, including chromosome 12 (3,027,081–120,462,673) and chromosome 15 (3,000,426–103,492,450). The array design was based on National Center for Biotechnology Information Build 36 of the mouse genome sequence, and median probe spacing was 656 bp. Kidney DNA from a pBx+/− mouse was used as a reference.

PCR and qPCR. PCR on genomic DNA from pBxAida+/− and pBxAida−/− plasma cell tumors was performed using previously published procedures (3, 32). EcoRI-digested and self-ligated DNA from tumor cell lines was amplified and subjected to inverse PCR, as previously described (70). For complete primer sequences see Table S4. We used degenerate primers to amplify rearranged heavy and light chain variable genes (36). Direct sequencing of PCR products was performed by the NCI sequencing core facility.

For qPCR, 2 ng cDNA was amplified using SYBR Green PCR Master Mix (Applied Biosystems) and 0.33 μM each of forward and reverse primer on a sequence detector system (ABI PRISM 7900HT; Applied Biosystems). Primers for qPCR were designed using the Primer Express software (Applied Biosystems) and synthesized at BioServe Biotechnologies. The primer sequences were as follows: v-Myc-F1:5'-TGAAGCCGCAAGTTTCCTG-3' c-Myc-R1:5'-GGACCTGGGCTGATCTTCC-3', N-Myc-F1:5'-CTGAGGCTGAGGACACAGAA-3', N-Myc-R1:5'-CCTGCGTGGCCCTTCAGA-3', GAPDH-F:5'-TGGTGTGCTGGTGAATCTGA-3', GAPDH-R:5'-CCTGCTTACCACCTTTCTG-3'. All samples were tested in triplicate, and mean values were used for quantification. Analysis was performed using SDS version 2.2 software (Applied Biosystems) according to the manufacturer’s instructions. Samples were normalized using the housekeeping gene Gapdh. The comparative CT method (ΔΔCT) was used for quantification of gene expression.

Southern blot analysis. Southern blotting was performed using standard procedures. Kidney DNA from a tumor-free pBxAida−/− was used as a control for DNA obtained from the 4885 and 4961 cell lines. DNAs were digested overnight with EcoRI or HindIII, and hybridization was performed with 32P-labeled moMy 9#303 or pJ11 probes provided by K. Huppi (NCI, Bethesda, MD). Images were scanned using the Typhoon imaging system (Molecular Dynamics).

Online supplemental material. Fig. S1 is a graphical representation of survival and tumor incidence in pristane-injected pBxAida−/− mice with or without antibiotic treatment. Fig. S2 presents histological evidence of exaggerated lymphoid neogenesis in lungs and oil granuloma tissue of pBxAida−/− mice containing multiple germinal center-like structures. Fig. S3 shows clonal Jh rearrangements in pBxAida−/− cell lines identified by Southern blotting. Fig. S4 is a scheme depicting the molecular structure of genetic alterations in pBxAida−/− cell lines. Table S1 shows a comparison of plasma cell tumor incidence in pAida−/− vs pAida+/− mice. Table S2 presents summary of FISH data showing proportions of IgH/c-Myc fusion signals in tissue sections. Table S3 shows results of PCR screening of AID-sufficient Bc·-transgenic mice for T(12;15)-translocation positive clones, and Table S4 provides sequences and positions of primers used for the screening. The online version of this article is available at http://www.jem.org/cgi/content/full/jem.20070882/DC1.

We thank Andre Nussenzweig (NCI), J. Frederic Mushinski (NCI), and Herbert C Morse III (National Institute of Allergy and Infectious Disease [NIAID]) for reading the manuscript and making valuable suggestions; Val Bliskovsky (NCI) for sequencing BACs and PCR products; Brad Burkholder (NCI) for genotyping, Rick Dreyfuss (NIH) for photo microscopy, and Jianjun Feng (NIAID) for assistance with Southern blotting. We are grateful to Konrad Huppi (NCI) and Makiko Takizawa (NIAMS) for sharing ideas and reagents; and Sabine Mai (Manitoba Institute of Cell Biology) for technical tips.

This work was supported by the Intramural Research Program of the National Institutes of Health (NCI and NIAID).

The authors have no conflicting financial interests.

Submitted: 3 May 2007
Accepted: 17 October 2007

REFERENCES

1. Ohno, S., M. Babonits, F. Wiener, J. Spira, G. Klein, and M. Potter. 1979. Nonrandom chromosome changes involving the Ig gene-carrying chromosomes 12 and 6 in pristane-induced mouse plasmacytomas. Cell. 18:1001–1007.

2. Suetsumu, S., T. Matusuka, T. Matsuda, S. Ohno, J.-I. Miyazaki, K.-I. Yamamura, T. Hiranu, and T. Kishimoto. 1992. Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc. Natl. Acad. Sci. USA. 89:232–235.

3. Kovalchuk, A.L., T. Kishimoto, and S. Janz. 2000. Lymph nodes and Peyer’s patches of IL-6 transgenic BALB/c mice harbor T(12;15) translocated plasma cells that contain illegitimate exchanges between the immunoglobulin heavy-chain mu locus and c-myc. Leukemia. 14:1127–1135.

4. Wiener, F., S. Silva, H. Sugiyama, M. Babonits, H. Axelsson, P. Chimnay, and G. Klein. 1990. Mouse plasmacytoma associated (MPC) T(15;16) translocation occurs repeatedly in new MPC induction system. Curr. Top. Microbiol. Immunol. 166:107–119.

5. Cory, S. 1986. Activation of cellular oncogenes in hematopoietic cells by chromosome translocation. Adv. Cancer Res. 47:189–211.

6. Corcoran, L.M., S. Cory, and J.M. Adams. 1988. Transposition of the immunoglobulin heavy-chain enhancer to the myc oncogene in a murine plasmacytoma. Cell. 40:71–79.

7. Fahrlander, P.D., J. Sumegi, J.-Q. Yang, F. Wiener, K.B. Marcu, and G. Klein. 1985. Activation of the c-myc oncogene by the immunoglobulin heavy-chain gene enhancer after multiple switch region-mediated chromosome rearrangements in a murine plasmacytoma. Proc. Natl. Acad. Sci. USA. 82:3746–3750.

8. Shapiro, M.A., and M. Weigert. 1987. A complex translocation at the murine kappa light-chain locus. Mol. Cell. Biol. 7:4130–4133.

9. Shaughnessy, J., F. Wiener, K. Huppi, J.P. Mushinski, and M. Potter. 1994. A novel c-myc-activating reciprocal T(12;15) chromosomal
translocation juxtaposes S alpha to Pev-1 in a mouse plasmacytoma. 

19. Ramiro, A.R., M. Jankovic, T. Eisenreich, S. Difilippantonio, S. Muramatsu, M. V.S. Sankaranand, S. Anant, M. Sugai, K. Kinoshita, N.O. Davidson, and T. Honjo. 1999. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminate family in germinal center B cells. J. Biol. Chem. 274: 18470–18476.

20. Muramatsu, M., K. Kinoshita, S. Fagarasan, S. Yamada, Y. Shinkai, and T. Honjo. 2000. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 102:553–563.

21. Revy, P., T. Muto, Y. Levy, F. Geissmann, A. Plebani, O. Sanal, N. Catalan, M. Ferveille, R. Dufourcq-Labeurle, A. Gennery, et al. 2000. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell. 102:565–575.

22. Petersen-Mahrt, S.K., R.S. Harris, and M.S. Neuberger. 2002. AID ecoli suggests a DNA deamination mechanism for antibody diversification. Nature. 418:99–103.

23. Franco, S., F.W. Alt, and J.P. Manis. 2006. Pathways that suppress programmed DNA breaks from progressing to chromosomal breaks and translocations. DNA Repair (Amst.). 5:1030–1041.

24. Lieber, M.R., K. Yu, and S.C. Raghavan. 2006. Roles of nonhomologous DNA end joining, V(DJ) recombination, and class switch recombination in chromosomal translocations. DNA Repair (Amst.). 5:1234–1245.

25. Doi, T., K. Kinoshita, M. Ikegawa, M. Muramatsu, and T. Honjo. 2003. De novo protein synthesis is required for the activation-induced cytidine deaminase function in class-switch recombination. Proc. Natl. Acad. Sci. USA. 100:2634–2638.

26. Begum, N.A., N. Izumi, M. Nishikori, H. Nagaoka, R. Shinkura, and T. Honjo. 2007. Requirement of non-canonical activity of uracil DNA glycosylase for class switch recombination. J. Biol. Chem. 282:731–742.

27. Ramiro, A.R., M. Jankovic, T. Eisenreich, S. Difilippantonio, S. Chen-Kiang, M. Muramatsu, T. Honjo, A. Nussenzweig, and M.C. Nussenzweig. 2004. AID is required for c-myc/IgH chromosome translocations in vivo. Cell. 118:431–438.

28. Ramiro, A.R., M.C. Nussenzweig, and A. Nussenzweig. 2006. Switching on by chromosomal translocations. Cancer Res. 66:7837–7839.

29. Byrd, L.G., A.H. McDonald, L.G. Gold, and M. Potter. 1991. Specific pathogen-free BALB/cAn mice are refractory to plasmacytoma induction by pristane. J. Immunol. 147:3632–3637.

30. Fagarasan, S., M. Muramatsu, K. Suzuki, H. Nagaoka, H. Hasi, and T. Honjo. 2002. Critical roles of activation-induced cytidine deaminase in the homeostasis of gut flora. Science. 298:1424–1427.

31. Silva, S., A.L. Kovachuk, J.S. Kim, G. Klein, and S. Janz. 2003. BCL2 accelerates inflammation-induced BALB/c plasmacytomas and promotes novel tumors with coexisting T(12;15) and T(6;15) translocations. Cancer Res. 63:8656–8663.

32. Cheung, W.C., J.S. Kim, M. Linden, L. Peng, B. Van Ness, R.D. Polakiewicz, and S. Janz. 2004. Novel targeted deregulation of c-Myc cooperates with Bcl-XL to cause plasma cell neoplasms in mice. J. Clin. Invest. 113:1763–1773.

33. Strasser, A., A.W. Harris, and S. Cory. 1993. E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells. Oncogene. 8:1–9.

34. Potter, M. 1984. Genetics of susceptibility to plasmacytoma development in BALB/c mice. Cancer Surv. 3:247–264.

35. Anderson, A.O., J.S. Wax, and M. Potter. 1985. Differences in the peritoneal response to pristane in BALB/AnPt and BALB/cj mice. Curr. Top. Microbiol. Immunol. 122:242–253.

36. Aloisi, F. and R. Pujol-Borrell. 2006. Lymphoid neogenesis in chronic inflammatory diseases. Nat. Rev. Immunol. 6:205–217.

37. Drayton, D.L., S. Liao, R.H. Mounzer, and N.H. Ruddle. 2006. Lymphoid organ development: from ontogeny to neogenesis. Nat. Immunol. 7:344–353.

38. Kovalchuk, A.L., E.B. Mushinski, and S. Janz. 2000. Clonal diversification of primary BALB/c plasmacytomas harboring T(12;15) chromosomal translocations. Leukemia. 14:909–921.

39. Wiener, F., and M. Potter. 1993. Myc-associated chromosomal translocations and rearrangements in plasmacytoma neogenesis in mice. In The causes and consequences of chromosomal aberrations. L.R. Kirsch, editor. CRC Press, Inc. Boca Raton, FL.

40. M. 1984. Genetics of susceptibility to plasmacytoma development in BALB/c mice. Cancer Surv. 3:247–264.

41. Anderson, A.O., J.S. Wax, and M. Potter. 1985. Differences in the peritoneal response to pristane in BALB/AnPt and BALB/cj mice. Curr. Top. Microbiol. Immunol. 122:242–253.

42. Aloisi, F. and R. Pujol-Borrell. 2006. Lymphoid neogenesis in chronic inflammatory diseases. Nat. Rev. Immunol. 6:205–217.

43. Drayton, D.L., S. Liao, R.H. Mounzer, and N.H. Ruddle. 2006. Lymphoid organ development: from ontogeny to neogenesis. Nat. Immunol. 7:344–353.

44. Komada, H., T. Hiroi, Y. Nishiyama, H. Takahashi, Y. Masunaga, S. Hachiman, S. Kamatogawa, H. Takahashi-Iwanaga, T. Iwanaga, H. Kiyono, et al. 2002. Identification of multiple isolated lymphoid follicles on the antimesenteric wall of the mouse small intestine. J. Immunol. 168:57–64.

45. Potter, M., and F. Wiener. 1992. Plasmacytoma neogenesis in mice: model of neoplastic development dependent upon chromosomal translocations. Cancerogenesis. 13:1681–1697.

46. Muller, J.R., S. Janz, and M. Potter. 1995. Differences between Burkitt's lymphomas and mouse plasmacytomas in the immunoglobulin heavy chain/c-myc recombinations that occur in their chromosomal translocations. Cancer Res. 55:5012–5018.

47. Kovalchuk, A.L., E.B. Mushinski, and S. Janz. 2000. Clonal diversification of primary BALB/c plasmacytomas harboring T(12;15) chromosomal translocations. Leukemia. 14:909–921.

48. Wiener, F., and M. Potter. 1993. Myc-associated chromosomal translocations and rearrangements in plasmacytoma neogenesis in mice. In The causes and consequences of chromosomal aberrations. L.R. Kirsch, editor. CRC Press, Inc. Boca Raton, FL.

49. M. 1984. Genetics of susceptibility to plasmacytoma development in BALB/c mice. Cancer Surv. 3:247–264.

50. Anderson, A.O., J.S. Wax, and M. Potter. 1985. Differences in the peritoneal response to pristane in BALB/AnPt and BALB/cj mice. Curr. Top. Microbiol. Immunol. 122:242–253.
48. Bassing, C.H., H. Sub, D.O. Ferguson, K.F. Chua, J. Manis, M. Eckersdorff, M. Gleason, R. Bromson, C. Lee, and F.W. Alt. 2003. Histone H2AX: a dosage–dependent suppressor of oncogenic translocations and tumors. Cell. 114:359–370.

49. Woo, Y., S.M. Wright, S.A. Maas, T.L. Alley, L.B. Caddle, S. Kamdar, J. Affourtit, O. Foreman, E.C. Akeson, D. Shaffer, et al. 2007. The nonhomologous end joining factor Artemis suppresses multi-tissue tumor formation and prevents loss of heterozygosity. OncoGene. 26: 6010–6020.

50. Roth, D.B., T.N. Porter, and J.H. Wilson. 1985. Mechanisms of nonhomologous recombination in mammalian cells. Mol. Cell. Biol. 5:2599–2607.

51. Roth, D.B. 2002. Amplifying mechanisms of lymphomagenesis. Mol. Cell. 10:1–2.

52. Weitzman, S.A., A.B. Weitberg, E.P. Clark, and T.P. Stossel. 1985. bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 4:291–299.

53. Barzilai, A., and K. Yamamoto. 2004. DNA damage responses to oxidative stress. DNA Repair (Amst.). 3:1109–1115.

54. Shacter, E., E.J. Beecham, J.M. Corey, K.W. Kohn, and M. Potter. 1988. Activated neutrophils induce prolonged DNA damage in neighboring cells. Carcinogenesis. 9:2297–2304.

55. Shacter, E., R.L. Lopez, E.J. Beecham, and S. Janz. 1990. DNA damage induced by phorbol ester-stimulated neutrophils is augmented by extracellular cofactors. J. Biol. Chem. 265:6693–6699.

56. Valko, M., M. Izakovic, M. Mazur, C.J. Rhodes, and J. Telser. 2004. Role of oxygen radicals in DNA damage and cancer incidence. Mol. Cell. Biochem. 266:37–56.

57. Tanaka, T., H.D. Halicka, X. Huang, F. Traganos, and Z. Darzynkiewicz. 2006. Constitutive histone H2AX phosphorylation and ATM activation, the reporters of DNA damage by endogenous oxidants. Cell Cycle. 5:1940–1945.

58. Vilenchik, M.M., and A.G. Knudson. 2003. Endogenous DNA double-strand breaks: production, fidelity of repair, and induction of cancer. Proc. Natl. Acad. Sci. USA. 100:12871–12876.

59. Fang, W., D.L. Mueller, C.A. Pennell, J.J. Rivard, Y.S. Li, R.R. Hardy, M.S. Schlissel, and T.W. Behrens. 1996. Frequent aberrant immunoglobulin gene rearrangements in pro-B cells revealed by a bcl-xL transgene. Immunity. 4:291–299.

60. Fang, W., B.C. Weintraub, B. Dunlap, P. Garside, K.A. Pape, M.K. Jenkins, C.C. Goodnow, D.L. Mueller, and T.W. Behrens. 1998. Self-reactive B lymphocytes overexpressing Bcl-xL escape negative selection and are tolerated by clonal anergy and receptor editing. Immunity. 9:35–45.

61. Alves, N.L., R.A. van Lier, and E. Elderling. 2007. Withdrawal symptoms on display: Bcl-2 members under investigation. Trends Immunol. 28:26–32.

62. Giono, L.E., and J.J. Manfredi. 2006. The p53 tumor suppressor participates in multiple cell cycle checkpoints. J. Cell. Physiol. 209:13–20.

63. Livingstone, L.R., A. White, J. Sprouse, E. Livanos, T. Jacks, and T.D. Troy. 1992. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell. 70:923–935.

64. Yin, Y., M.A. Tainsky, F.Z. Bischoff, L.C. Strong, and G.M. Wahl. 1992. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell. 70:937–948.

65. Askew, D.S., R.A. Ashmun, B.C. Simmons, and J.L. Cleveland. 1991. Constitutive c-myc expression in an IL-3–dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. OncoGene. 6: 1915–1922.

66. Evan, G.I., A.H. Wyllie, C.S. Gilbert, T.D. Littlewood, H. Land, M. Brooks, C.M. Waters, L.Z. Penn, and D.C. Hancock. 1992. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 69:119–128.

67. Grillot, D.A., R. Merino, J.C. Pena, W.C. Fanslow, F.D. Finkelman, C.B. Thompson, and G. Nunez. 1996. bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice. J. Exp. Med. 183:381–391.

68. Boise, L.H., M. Gonzalez-Garcia, C.E. Postema, L. Ding, T. Lindsten, L.A. Turka, X. Mao, G. Nunez, and C.B. Thompson. 1993. bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 74:597–608.

69. Liyanage, M., A. Coleman, S. du Manoir, T. Veldman, S. McCormack, R.B. Dickson, C. Barlow, A. Wynshaw-Boris, S. Janz, J. Wienberg, et al. 1996. Multicolour spectral karyotyping of mouse chromosomes. Nat. Genet. 14:312–315.

70. Chu, C.C., W.E. Paul, and E.E. Max. 1992. Quantitation of immunoglobulin mu-gamma 1 heavy chain switch region recombination by a digestion-circularization polymerase chain reaction method. Proc. Natl. Acad. Sci. USA. 89:6978–6982.